NEW YORK, July 31, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and LifePoint Hospitals, Inc. (NASDAQ: LPNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences, Inc. Research Report
On July 25, 2013, Gilead Sciences, Inc. (Gilead) reported its financial results for Q2 2013. The Company reported that its total revenues during Q2 2013 increased 15.1% YoY to $2.8 billion, with product sales increasing 14.5% YoY to $2.7 billion, and royalty, contract, and other revenues increasing 31.2% YoY to $110.1 million. Net income attributable to Gilead was $772.6 million, or $0.46 per diluted share, in Q2 2013, compared to $711.6 million, or $0.46 per diluted share, in Q2 2012. Further, non-GAAP net income for Q2 2013, which excludes acquisition-related, restructuring, and stock-based compensation expense, was $839.7 million or $0.50 per diluted share, compared to $767.3 million or $0.49 per diluted share, in Q2 2012. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9898_GILD]
Pfizer Inc. Research Report
On July 25, 2013, Pfizer Inc. (Pfizer) expressed disappointment after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) re-confirmed its April 25, 2013, decision to recommend against approval of XELJANZ (tofacitinib citrate) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Pfizer stated that after a re-examination of the application as requested by the Company, the CHMP is of the opinion that XELJANZ does not demonstrate a favorable benefit-risk profile. Dr. Steven Romano, Senior Vice President and the head of the Medicines Development Group for Pfizer Special Care, said, "The clinical experience with XELJANZ to date, which includes data from approximately 5,000 patients treated for RA, demonstrates a consistent efficacy and safety profile across a range of patient types and a risk profile that is familiar to rheumatologists who have experience utilizing the range of treatments available to treat this disease. We believe that the benefit:risk profile of XELJANZ is favorable, and we remain committed to working with the EMA to make XELJANZ available to appropriate patients in Europe." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]
Merck & Co., Inc. Research Report
On July 26, 2013, Merck & Co., Inc. (Merck) issued a statement regarding the conclusion of the EMA for CHMP review of GLP-1, or incretin-based therapies, including sitagliptin. According to the EMA, "Investigation into GLP-1 based diabetes therapies concluded: No new concerns for GLP-1 therapies identified on the basis of available evidence." Michael Rosenblatt, M.D., Executive Vice President and Chief Medical Officer of Merck, said, "We are confident in the safety profile of sitagliptin, an important medicine to help adults with type 2 diabetes lower their blood sugar levels." He added, "The efficacy and safety profile of sitagliptin supports its use in a wide range of adult patients with type 2 diabetes. We will continue to monitor the safety of sitagliptin in close collaboration with regulatory agencies and scientific experts." The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]
AbbVie Inc. Research Report
On July 26, 2013, AbbVie Inc. (AbbVie) reported its financial results for Q2 2013. The Company reported that its net sales grew 4.4% YoY to $4.7 billion, primarily driven by the continued strength of HUMIRA, as well as double-digit growth from key products including Synthroid, Creon, Zemplar, and Duodopa. Net earnings were $1.1 billion, or $0.66 per diluted share, in Q2 2013, compared to $1.3 billion, or $0.80 per diluted share, in Q2 2012. The Company also updated its diluted EPS guidance for full-year 2013 to $3.07 to $3.13 (from $3.03 to $3.13) on an adjusted basis or $2.66 to $2.72 on a GAAP basis, excluding $0.41 per share of intangible asset amortization expense, acquired in-process research and development, and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]
LifePoint Hospitals, Inc. Research Report
On July 26, 2013, LifePoint Hospitals, Inc. (LifePoint) reported its financial results for Q2 2013. The Company reported that its revenues increased 8.2% YoY to $894.9 million during Q2 2013. Net income attributable to LifePoint was $27.4 million, or $0.57 per diluted share, in Q2 2013 compared to net income attributable to LifePoint of $40.3 million, or $0.83 per diluted share, in Q2 2012.Commenting on the results, William F. Carpenter III, Chairman and CEO of LifePoint, said, "We continue to position LifePoint to benefit from healthcare reform in a challenging operating environment. Our growth and quality initiatives drove sequential improvements in outpatient and inpatient volumes this quarter, while our M&A program allowed us to build out our networks in several key regions." The Full Research Report on LifePoint Hospitals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f06d_LPNT]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner